A Visual Autism Subtype Left a Fusiform Lipid Signature TL;DR: A Molecular Psychiatry study suggests that autistic children with atypical visual processing carry a distinct fusiform gyrus lipid-myelin signature, tied to low ceruloplasmin and strong MRI-based subtype discrimination. Key Findings Fusiform subtype emerged in 288 children: The study included 90 autistic children with atypical visual …
Alpha-Synuclein Testing Could Clarify Dementia Diagnosis TL;DR: In 398 memory-clinic patients, alpha-synuclein seed testing identified Lewy body dementia with 95% sensitivity and revealed hidden synuclein positivity in 15.8% of Alzheimer’s disease cases. Key Findings Seed testing separated Lewy body dementia: The ALZAN cohort recruited memory-clinic patients from Montpellier, Nimes, and Perpignan between November 2022 and …
150 mg Caffeine Did Not Trigger Panic Disorder Anxiety TL;DR: A normal coffee-sized caffeine dose did not trigger a subjective anxiety surge in panic disorder, but it did make people more physiologically aroused, more avoidant, and more distracted by bodily sensations. Key Findings 150 mg did not raise subjective anxiety: The primary outcome did not …
Broken Blood Vessels May Drive Alzheimer’s Decline TL;DR: A new study reveals that impaired cerebrovascular function—the brain’s ability to regulate blood flow—correlates strongly with Alzheimer’s symptoms, offering a potential non-invasive way to detect early cognitive decline. Alzheimer’s disease has long been framed as a problem of toxic protein accumulation: amyloid plaques and tau tangles strangling …
Metformin’s Secret Weapon: How the Brain Controls Blood Sugar TL;DR: Metformin’s glucose-lowering effect depends on a brain signaling pathway—it inhibits Rap1 in the hypothalamus, activating neurons that tell the liver to stop overproducing glucose. For decades, metformin has been the first-line drug for type 2 diabetes, working so reliably that millions take it daily. Yet …
How the Brain Hijacks Balance Control in Parkinson’s TL;DR: When older adults face large balance challenges, their brains shift from relying on quick brainstem reflexes to slower cortical circuits—a shift that happens even in Parkinson’s disease, revealing a mechanistic window into age-related balance loss. Balance isn’t automatic. When you stumble forward or feel the ground …
How Lecanemab Clears Brain Amyloid: The Microglia Key TL;DR: Lecanemab, the first Alzheimer’s antibody to slow cognitive decline, works by activating immune cells called microglia through a specific immune signaling pathway, with the molecule SPP1/osteopontin playing a critical role in triggering the brain’s own cleanup machinery. When lecanemab was approved by the FDA, it sparked …
Cell-Type Gene Networks Reveal Hidden Causes of Alzheimer’s TL;DR: Researchers mapped how genes are regulated differently across six brain cell types in Alzheimer’s disease, discovering that excitatory neurons drive the most extensive regulatory disruptions—and identifying key hub genes like RPS27A that could become therapeutic targets. Alzheimer’s disease is a disease of broken communication. The brain …
Chlorpyrifos Linked to 2.5x Higher Parkinson’s Risk TL;DR: A pesticide sprayed on US crops decades ago more than doubles your risk of Parkinson’s disease, and new research shows exactly how it damages dopamine neurons. You probably never heard of chlorpyrifos, but your neighborhood may have been sprayed with it. This common agricultural insecticide was applied …
The Death Complex Fueling Alzheimer’s (And How to Stop It) TL;DR: Researchers discovered a toxic interaction between two brain proteins—NMDAR and TRPM4—that drives neurodegeneration in Alzheimer’s disease, and a small molecule called FP802 that blocks this “death complex” and prevents cognitive decline in mice. Alzheimer’s disease devastates the brain through multiple pathways, but the exact …
